Adding Atezolizumab to Chemotherapy Improves Patient Outcomes in Early TNBC
December 11th 2020Pathologic complete responses were improved when neoadjuvant atezolizumab was added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide compared with placebo in combination with chemotherapy as treatment of patients with early triple-negative breast cancer without adding additional treatment burden to patients.
Read More
Ipatasertib Plus Paclitaxel Combo Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC
December 11th 2020Ipatasertib in combination with paclitaxel failed to demonstrate a significant improvement in progression-free survival compared with placebo plus paclitaxel as treatment of patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.
Read More
Sacituzumab govitecan demonstrated clinical benefit compared with physician’s choice of therapy as treatment of patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, but greater efficacy was seen in patients with a medium or high Trop-2 score.
Read More
Pembrolizumab Added to Various Frontline Chemo Regimens Induces Antitumor Activity in Advanced TNBC
December 10th 2020Subgroup analyses of a phase 3 randomized trial continue to support a role for the addition of pembrolizumab to chemotherapy in the frontline setting for patients with advanced triple-negative breast cancer, with the greatest benefit derived by those with higher PD-L1 expression by combined positive score.
Read More
Compared with women in the general population, those who survive breast cancer experience more difficulty in becoming pregnant and have a risk of preterm labor, although a systematic review and meta-analysis demonstrated that most deliver healthy babies with no detrimental effects on their long-term survival.
Read More
Alpelisib in combination with letrozole demonstrated sustained efficacy and no new safety signals as treatment of patients with PIK3CA-mutant HR–positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant.
Read More
BluePrint Subtyping May Predict Benefit of Adjuvant Pertuzumab in Early Breast Cancer
December 10th 2020Adjuvant treatment with pertuzumab demonstrated a trend for greater benefit in patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay.
Read More
Fewer Deaths, CNS Benefit Observed With Adjuvant Neratinib in Early-Stage HER2+ Breast Cancer
December 10th 2020The cumulative incidence of central nervous system recurrences was improved, and fewer deaths were observed with adjuvant neratinib as treatment of patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy compared with placebo at 8 years of follow-up.
Read More
CTC Count Possible Biomarker for Using HER2-Directed Therapy in MBC
December 10th 2020Favorable outcomes after treatment with the HER2-directed lapatinib were indicated by early declines in circulating tumor cell counts in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs, suggesting this could serve as a clinical biomarker.
Read More
Trilaciclib Administered Prior to Chemotherapy Enhances Immune System Reaction in Metastatic TNBC
December 10th 2020The addition of trilaciclib prior to gemcitabine and carboplatin chemotherapy significantly improved overall survival in patients with previously treated metastatic triple-negative breast cancer.
Read More
Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.
Read More
Ribociclib Maintains Significant Survival Benefit in HR+/HER2– Breast Cancer
December 10th 2020In the phase 3 MONALEESA-7 trial, patients with hormone receptor–positive, HER2-negative breast cancer had a significant improvement in overall survival and chemotherapy delay when treated with ribociclib plus endocrine therapy compared with placebo.
Read More
Omission of Postoperative Radiotherapy Has No Effect on Metastatic Risk in Low-Grade Breast Cancer
December 10th 2020The use of whole breast irradiation can be omitted in patients 65 years and older with pT1-2 tumors on local control at 10 years after breast-conserving surgery and adjuvant endocrine therapy in low risk, older patients.
Read More
Oral Paclitaxel Combination Reduces the Risk of Death in Patients With mBC
December 9th 2020In the phase 3 KX-ORAX-001 clinical trial, treatment with paclitaxel in combination with encequidar achieved a 26.5% reduction in the risk of death compared with paclitaxel by intravenous injection in patients with metastatic breast cancer.
Read More
Ribociclib Therapy Is Informed by HR+/HER2– Breast Cancer Intrinsic Subtype
December 9th 2020A retrospective exploratory analysis of 3 trials of ribociclib in patients with hormone receptor–positive, HER2-negative advanced breast cancer confirmed the prognostic value of intrinsic tumor subtype for efficacy outcomes with CDK4/6 inhibition.
Read More
Prediction of OS Accomplished With Follow-Up CTC Assessments in Patients with mBC
December 9th 2020Serial circulating tumor cell enumeration in patients with metastatic breast cancer has been shown to strongly predict overall survival outcomes. The prediction is possible when CTC assessments are performed at a median of 29 days following treatment initiation.
Read More
Data from a 29-practice consortium shows that oncologists tend to under-recognize substantial symptoms among patients with breast cancer receiving radiotherapy after they have undergone a lumpectomy, according to a presentation during the 2020 San Antonio Breast Cancer Symposium. The data underscore a need for improvement in symptom detection.
Read More
Invasive disease-free survival was prolonged in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer treated with abemaciclib in combination with standard endocrine therapy in the phase 3 monarchE trial, according to a presentation at the 2020 San Antonio Breast Cancer Symposium.
Read More
Premenopausal Women With Lymph Node+, HR+/HER2- Breast Cancer Benefit From Chemotherapy Addition
December 9th 2020Five-year invasive disease-free survival and overall survival were improved with the addition of chemotherapy to endocrine therapy as treatment of premenopausal, but not postmenopausal, women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.
Read More
Clinical Efficacy Observed With BCMA-Directed ADC MEDI2228 in Triple-Refractory Myeloma
December 9th 2020MEDI2228 demonstrated promising clinical efficacy as treatment of patients with relapsed/refractory multiple myeloma with triple-refractory disease experiencing maintained responses in a phase 1 study.
Read More
Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy
December 9th 2020An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Read More
Higher CPX-351 Induction Doses Lead to Delayed Hematologic Recovery in AML
December 8th 2020Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.
Read More
Results of Selinexor Added to Pd Regimen Moves Myeloma Study on to Phase 3
December 8th 2020The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.
Read More